Understanding Patient Experiences in Glioblastoma Clinical Research
This observational study aims to understand why people with glioblastoma multiforme (a type of brain cancer) choose to join or leave clinical trials. Researchers want to identify what helps or hinders participation, and the reasons for stopping a trial early. This study doesn't test a new treatment; instead, it gathers information from 500 participants to improve future clinical trials for glioblastoma patients. You could be eligible if you have a glioblastoma diagnosis, haven't had prior treatment for it, and are able to give informed consent. The study will look at how many people enroll within 3 months and how many stay until the end of a trial, measured at 12 months.
- Study design
- This is an observational study with a planned enrollment of 500 participants. It is not testing a specific intervention or drug.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study measures how many participants remain in a clinical trial until completion at 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michael B Gill · STUDY_DIRECTOR · Power Life Sciences Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Rate of patients who decide to enroll in a glioblastoma multiforme clinical study.3 months
- Number of glioblastoma multiforme study participants who remain in clinical trial until completion.12 months